[1]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Dis-ease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology (Baltimore, Md.), 64, 73-84.
https://doi.org/10.1002/hep.28431
|
[2]
|
Younossi, Z.M., Ratziu, V., Loomba, R., et al. (2019) Obeticholic Acid for the Treatment of Non-Alcoholic Steatohepatitis: Interim Analysis from a Multicentre, Randomised, Placebo-Controlled Phase 3 Trial. The Lancet, 394, 2184-2196.
|
[3]
|
Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Metabolism: Clinical and Experimental, 65, 1038-1048.
https://doi.org/10.1016/j.metabol.2015.12.012
|
[4]
|
Goldberg, D., Ditah, I.C., Saeian, K., et al. (2017) Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease among Patients with Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation. Gastroenterology, 152, 1090-1099. https://doi.org/10.1053/j.gastro.2017.01.003
|
[5]
|
Younossi, Z., Anstee, Q.M., Marietti, M., et al. (2018) Global Burden of NAFLD and NASH: Trends, Predictions, Risk Factors and Prevention. Nature Reviews. Gastroenterology & Hepatology, 15, 11-20.
https://doi.org/10.1038/nrgastro.2017.109
|
[6]
|
Ye, Q., Zou, B., Yeo, Y.H., et al. (2020) Global Prevalence, Inci-dence, and Outcomes of Non-Obese or Lean Non-Alcoholic Fatty Liver Disease: A Systematic Review and Me-ta-Analysis. The Lancet. Gastroenterology & Hepatology, 5, 739-752. https://doi.org/10.1016/S2468-1253(20)30077-7
|
[7]
|
Ratziu, V. (2018) A Critical Review of Endpoints for Non-Cirrhotic NASH Therapeutic Trials. Journal of Hepatology, 68, 353-361. https://doi.org/10.1016/j.jhep.2017.12.001
|
[8]
|
Kremoser, C. (2021) FXR Agonists for NASH: How Are They Different and What Difference Do They Make? Journal of Hepatology, 75, 12-15. https://doi.org/10.1016/j.jhep.2021.03.020
|
[9]
|
Cobbina, E. and Akhlaghi, F. (2017) Non-Alcoholic Fatty Liver Disease (NAFLD)—Pathogenesis, Classification, and Effect on Drug Metabolizing Enzymes and Transporters. Drug Metabolism Reviews, 49, 197-211.
https://doi.org/10.1080/03602532.2017.1293683
|
[10]
|
Friedman, S.L., Neuschwander-Tetri, B.A., Rinella, M., et al. (2018) Mechanisms of NAFLD Development and Therapeutic Strategies. Nature Medicine, 24, 908-922. https://doi.org/10.1038/s41591-018-0104-9
|
[11]
|
Attia, S.L., Softic, S. and Mouzaki, M. (2021) Evolving Role for Pharmacotherapy in NAFLD/NASH. Clinical and Translational Science, 14, 11-19. https://doi.org/10.1111/cts.12839
|
[12]
|
Chow, M.D., Lee, Y. and Guo, G.L. (2017) The Role of Bile Acids in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Molecular Aspects of Medicine, 56, 34-44. https://doi.org/10.1016/j.mam.2017.04.004
|
[13]
|
Guo, C., LaCerte, C., Edwards, J.E., et al. (2018) Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. The Journal of Pharmacology and Experimental Thera-peutics, 365, 413-421.
https://doi.org/10.1124/jpet.117.246033
|
[14]
|
Adorini, L., Pruzanski, M. and Shapiro, D. (2012) Farnesoid X Re-ceptor Targeting to Treat Nonalcoholic Steatohepatitis. Drug Discovery Today, 17, 988-997. https://doi.org/10.1016/j.drudis.2012.05.012
|
[15]
|
Cariou, B., van Harmelen, K., Duran-Sandoval, D., et al. (2006) The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice. The Journal of Biological Chemistry, 281, 11039-11049.
https://doi.org/10.1074/jbc.M510258200
|
[16]
|
Ma, K., Saha, P.K., Chan, L., et al. (2006) Farnesoid X Receptor Is Essential for Normal Glucose Homeostasis. Journal of Clinical Investigation, 116, 1102-1109. https://doi.org/10.1172/JCI25604
|
[17]
|
Zhang, Y., Lee, F.Y., Barrera, G., et al. (2006) Activation of the Nuclear Receptor FXR Improves Hyperglycemia and Hyperlipidemia in Diabetic Mice. Proceedings of the National Academy of Sciences of the United States of America, 103, 1006-1011. https://doi.org/10.1073/pnas.0506982103
|
[18]
|
Rizzo, G., Disante, M., Mencarelli, A., et al. (2006) The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo. Molecular Pharmacology, 70, 1164-1173.
https://doi.org/10.1124/mol.106.023820
|
[19]
|
Hollman, D.A.A., Milona, A., van Erpecum, K.J., et al. (2012) An-ti-Inflammatory and Metabolic Actions of FXR: Insights into Molecular Mechanisms. Biochimica et Biophysica Acta, 1821, 1443-1452.
https://doi.org/10.1016/j.bbalip.2012.07.004
|
[20]
|
Trauner, M., Fuchs, C.D., Halilbasic, E., et al. (2017) New Therapeutic Concepts in Bile Acid Transport and Signaling for Management of Cholestasis. Hepatology (Baltimore, Md.), 65, 1393-1404. https://doi.org/10.1002/hep.28991
|
[21]
|
Jhaveri, M.A. and Kowdley, K.V. (2017) New De-velopments in the Treatment of Primary Biliary Cholangitis—Role of Obeticholic Acid. Therapeutics and Clinical Risk Management, 13, 1053-1060.
https://doi.org/10.2147/TCRM.S113052
|
[22]
|
Song, K., Li, T., Owsley, E., et al. (2009) Bile Acids Activate Fi-broblast Growth Factor 19 Signaling in Human Hepatocytes to Inhibit Cholesterol 7alpha-Hydroxylase Gene Expression. Hepatology (Baltimore, Md.), 49, 297-305.
https://doi.org/10.1002/hep.22627
|
[23]
|
Kir, S., Beddow, S.A., Samuel, V.T., et al. (2011) FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science (New York, N.Y.), 331, 1621-1624. https://doi.org/10.1126/science.1198363
|
[24]
|
Manne, V. and Kowdley, K.V. (2019) Obeticholic Acid in Primary Biliary Cholangitis: Where We Stand. Current Opinion in Gastroenterology, 35, 191-196. https://doi.org/10.1097/MOG.0000000000000525
|
[25]
|
Larter, C.Z., Chitturi, S., Heydet, D., et al. (2010) A Fresh Look at NASH Pathogenesis. Part 1: The Metabolic Movers. Journal of Gastroenterology and Hepatology, 25, 672-690. https://doi.org/10.1111/j.1440-1746.2010.06253.x
|
[26]
|
Mudaliar, S., Henry, R.R., Sanyal, A.J., et al. (2013) Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease. Gastroenterology, 145, 574-582.
https://doi.org/10.1053/j.gastro.2013.05.042
|
[27]
|
Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. (2015) Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-Cirrhotic, Non-Alcoholic Steatohepatitis (FLINT): A Multicentre, Randomised, Placebo-Controlled Trial. The Lancet (London, England), 385, 956-965. https://doi.org/10.1016/S0140-6736(14)61933-4
|
[28]
|
Pockros, P.J., Fuchs, M., Freilich, B., et al. (2019) CONTROL: A Randomized Phase 2 Study of Obeticholic Acid and Atorvastatin on Lipoproteins in Nonalcoholic Steatohepatitis Patients. Liver International, 39, 2082-2093.
https://doi.org/10.1111/liv.14209
|
[29]
|
Al-Dury, S., Wahlström, A., Panzitt, K., et al. (2019) Obeticholic Acid May Increase the Risk of Gallstone Formation in Susceptible Patients. Journal of Hepatology, 71, 986-991. https://doi.org/10.1016/j.jhep.2019.06.011
|
[30]
|
Mullard, A. (2020) FDA Rejects NASH Drug. Nature Reviews Drug Discovery, 19, 501.
https://doi.org/10.1038/d41573-020-00126-9
|